

Amendments to the Claims

1-40. (canceled)

41. (previously presented) An isolated peptide less than 15 amino acids in length comprising an oligopeptide selected from the group consisting of:

QAFTFSPTYK (SEQ ID NO:638);

LVVDFSQFSR (SEQ ID NO:620);

NVSIPWTHK (SEQ ID NO:625); and

SAICSVVRR (SEQ ID NO:653).

42. (previously presented) The peptide of claim 41, wherein said peptide is 11 amino acids in length.

43. (previously presented) The peptide of claim 41, wherein said peptide is 10 amino acids in length.

44. (withdrawn) The peptide of claim 41, wherein said peptide is 9 amino acids in length, and wherein said oligopeptide is selected from the group consisting of:

NVSIPWTHK (SEQ ID NO:625); and

SAICSVVRR (SEQ ID NO:653).

45. (previously presented) The peptide of claim 41, wherein said peptide is fused to a T helper peptide.

46. (previously presented) The peptide of claim 41, wherein said peptide is fused to spacer or linker amino acids.
47. (previously presented) The peptide of claim 41, wherein said peptide is fused to a carrier.
48. (previously presented) The peptide of claim 41, wherein said peptide is linked to a lipid.
49. (previously presented) A fusion protein comprising the peptide of claim 41.
50. (previously presented) A homopolymer of the peptide of claim 41.
51. (previously presented) A heteropolymer of the peptide of claim 41 and a different peptide.
52. (previously presented) A composition comprising the peptide of claim 41 and a carrier.
53. (previously presented) A pharmaceutical composition comprising the peptide of claim 41 and a pharmaceutically acceptable carrier.
54. (previously presented) A composition comprising the peptide of claim 41 and a liposome.
55. (previously presented) A composition comprising the peptide of claim 41 and one or more second peptides.

56. (currently amended) The composition of claim 55[[54]], wherein said peptides form a fusion protein.

57. (currently amended) The composition of claim 55[[54]], further comprising a carrier.

58. (currently amended) A pharmaceutical composition comprising the composition of claim 55[[54]] and a pharmaceutically acceptable carrier.

59. (currently amended) The composition of claim 55[[54]], wherein said peptides are fused by spacer or linker amino acids.